Abstract
BackgroundKidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion after vaccination are lower among patients with CKD and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19.MethodsThis investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and seven healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36, and 58 days after the first injection.ResultsIn controls, we detected antibodies at a positive level (>13 arbitrary units per ml; AU/ml) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0–1662.0). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml; IQR, 83.4–526.0). We detected a positive antibody level in only three transplant recipients at day 36. In patients on hemodialysis, those aged <75 years had a higher antibody response versus those aged >75 years, and serum albumin and Kt/V were positively correlated with serological response (P<0.04 and P<0.0, respectively); nonresponders to HBV vaccine had the lowest anti–SARS-CoV-2 antibody titers.ConclusionsOur results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, and is reduced by the uremic condition in patients undergoing hemodialysis.
Publisher
American Society of Nephrology (ASN)
Subject
Nephrology,General Medicine
Reference19 articles.
1. Kronbichler A , Anders HJ , Fernandez-Juárez GM , Floege J , Goumenos D , Segelmark M , .; Immunonephrology Working Group of the ERA-EDTA (European Renal Association – European Dialysis, Transplant Association): Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases [published online ahead of print March 9, 2021]. Nephrol Dial Transplant
2. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
4. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults;Mulligan;Nature,2020
5. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation;Krueger;Am J Kidney Dis,2020
Cited by
148 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献